drugset / Trial / NCT05737615

PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9

NCT05737615 ↗

NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to find the highest safe dose of hu5B1-TCO and the best dosing schedule of hu5B1-TCO and 64Cu-Tz-SarAr for finding cancer cells that are CA19-9 positive. This study will also help to find out how much radiation the body is exposed to when 64Cu-Tz-SarAr is used, and provide information on the way the body absorbs, distributes, and gets rid of 64Cu-Tz-SarAr.

Timeline

Start
2023-02-10
Primary completion
2026-02-10
Completion
2026-02-10

Outcome

Outcome not reported

Stopped: “Study tracer is currently unavailable”

Drugs

EvaluationDrugModalityDoseRoute
Subject 64Cu-Tz-SarAr Diagnostic / imaging agent — Intravenous
Subject hu5B1-TCO Protein / enzyme biologic — Intravenous